Drugs / Perhexiline
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials · 2 met primary | ||||||
| Phase 2 | NCT04426578 | Dec 2020 → Aug 2022 | hypertrophic cardiomyopathy | Flinders University | Unknown | No outcome recorded |
| Phase 2 | NCT02862600 | Aug 2016 → Apr 2017 | familial hypertrophic cardiomyopathy | Heart Metabolics Limited | Terminated | No outcome recorded |
| Phase 2 | NCT00839228 | Mar 2009 → Feb 2014 | diastolic heart failure | University of Aberdeen | Completed | No outcome recorded |
| Phase 2 | NCT00841139 | Feb 2009 → Sep 2011 | heart failure | University Hospital Birmingham NHS Foundation Trust | Completed | Met primary |
| Phase 2 | NCT00500552 | Dec 2006 → Aug 2010 | hypertrophic cardiomyopathy | University Hospital Birmingham | Completed | Met primary |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT00989508 | Oct 2009 → Sep 2012 | heart failure, intrinsic cardiomyopathy, myocardial infarction | University Hospital Birmingham | Unknown | No outcome recorded |
| Phase 2/3 | NCT00845364 | Feb 2007 → Apr 2010 | myocardial disorder | University Hospital Birmingham | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT02431221 | ? → Jul 2017 | hypertrophic cardiomyopathy | Heart Metabolics Limited | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00628056 Comparator | Oct 2006 → Apr 2009 | intrinsic cardiomyopathy | University Hospital Birmingham | Unknown | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Perhexiline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04426578 ↗ |
| Known as | NSC-758409 | ChEMBL registry synonym — accepted as the source's own label CHEMBL75880 ↗ |
| Known as | Perhexilina | ChEMBL registry synonym — accepted as the source's own label CHEMBL75880 ↗ |
| Known as | perhexiline maleate | “perhexiline maleate, oral, 25mg or 100mg tablets Whenever initiating PHM therapy, subjects will receive a loading regimen of PHM as indicated in in the Heart Metabolics Dose...” NCT02431221 ↗ |
| Known as | Perhexilinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL75880 ↗ |
| Known as | Pexid | ChEMBL registry synonym — accepted as the source's own label CHEMBL75880 ↗ |
| Known as | Pexsig | ChEMBL registry synonym — accepted as the source's own label CHEMBL75880 ↗ |
| Action | Inhibit | “Perhexiline acts by inhibiting both carnitine palmitoyl transferase-1 (CPT-1) and CPT-2” NCT00841139 ↗3“Carnitine O-palmitoyltransferase 1, muscle isoform inhibitor” CHEMBL75880 ↗ “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL75880 ↗ “Carnitine palmitoyltransferase 2 inhibitor” CHEMBL75880 ↗ |
| Modality | Small molecule | — CHEMBL75880 ↗ |
| Route | Oral | “patients at two centres were randomized to receive either oral perhexiline or placebo for at least 5 days prior to surgery” PMID 24948413 ↗ Jun 2014 |
| Target | CPT1B | “Carnitine O-palmitoyltransferase 1, muscle isoform inhibitor” CHEMBL75880 ↗ |
| Target | CPT2 | “Carnitine palmitoyltransferase 2 inhibitor” CHEMBL75880 ↗ |
| Target | MTOR | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL75880 ↗ |